0000950170-23-001898 | 10-Q | XBRL Viewer

Stock-based Compensation Plans (Tables)

3 Months Ended

Dec. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based compensation expense was reported as follows in the condensed consolidated statements of operations:


	Three Months Ended
	December 31,
(In thousands)	2022		2021
Product costs	$	67	$	30
Research and development		374		453
Selling, general and administrative		1,524		1,197
Total	$	1,965	$	1,680

Summary of Stock Option Grant Activity

Stock option grant activity was as follows:


	Three Months Ended December 31,
	2022		2021
Stock option grant activity:
Stock options granted		269,000		245,000
Weighted average grant date fair value	$	15.53	$	16.36
Weighted average exercise price	$	35.97	$	43.93

Net Loss Per Share Data (Tables)

3 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Denominator for Computation of Diluted Weighted Average Shares Outstanding

The following table presents the denominator for the computation of diluted weighted average shares outstanding:


	Three Months Ended
	December 31,
(In thousands)	2022		2021
Basic weighted average shares outstanding		13,983		13,878
Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units		—		—
Diluted weighted average shares outstanding		13,983		13,878

Derivative Financial Instruments

3 Months Ended

Dec. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

7. Derivative Financial Instruments

We periodically enter into interest rate swaps with major financial institutions of high credit quality to mitigate exposure to changes in interest rates on our floating-rate indebtedness. Since the fair value of these interest rate swaps is derived from current market rates, they are classified as derivative financial instruments. We do not use derivatives for speculative or trading purposes.

When the Company has multiple derivative financial instruments with the same counterparty subject to a master netting arrangement, we have elected to offset the amounts: (i) recorded as assets and liabilities and (ii) amounts recognized for the right to reclaim cash collateral we have deposited with the counterparty (i.e., cash collateral receivable). Such offset amounts are presented as either a net asset or liability by counterparty on the condensed consolidated balance sheets.

Cash Flow Hedge — Interest Rate Swap

On October 14, 2022, we entered into a floating-to-fixed interest rate swap agreement to mitigate exposure to interest rate increases related to our Term Loans. See Note 6 Debt for further information on our financing arrangements. The total notional amount of the interest rate swap was $25 million as of December 31, 2022. The interest rate swap agreement expires October 1, 2027. As a result of this agreement, every month we pay fixed interest at 4.455% in exchange for interest received at Term SOFR, and the fixed interest rate per annum on the first $25 million of notional value of the Term Loans will be 10.205% through its maturity. The interest rate swap agreement requires the Company to make deposits of cash collateral, which may increase or be refunded commensurate with fluctuations in current and forecasted interest rates. We have the contractual right to reclaim this cash collateral receivable.

The interest rate swap has been designated as a cash flow hedge. Consequently, changes in the fair value of the interest rate swap are recorded in accumulated other comprehensive loss ("AOCL") within stockholders' equity on the condensed consolidated balance sheets. The unrealized (losses) gains on the interest rate swap associated with the interest payments on the Term Loans that are still forecasted to occur are included in AOCL. These (losses) gains will be reclassified into interest expense on the condensed consolidated statements of operations over the life of the swap agreement as the hedged interest payments occur. Upon termination of the derivative instrument or a change in the hedged item, any remaining fair value recorded on the condensed consolidated balance sheets will be recorded as interest expense consistent with the cash flows associated with the underlying hedged item. Cash flows associated with the interest rate swap are included in cash flows from operating activities on the condensed consolidated statements of cash flows.

The net fair value of designated hedge derivatives subject to master netting arrangements reported on the condensed consolidated balance sheets was as follows:


	Asset (Liability)
(In thousands)	Gross Recognized Amount			Gross Offset Amount		Net Amount Presented			Cash Collateral Receivable		Net Amount Reported		Balance Sheet Location
December 31, 2022
Interest rate swap	$	(413	)	$	—	$	(413	)	$	533	$	120	Other assets, noncurrent
September 30, 2022
—	$	—		$	—	$	—		$	—	$	—	—

The pretax amounts recognized in AOCL on the interest rate swap were as follows:


	Three Months Ended December 31,
(In thousands)	2022			2021
Beginning unrealized net loss in AOCL	$	—		$	—
Net loss recognized in other comprehensive income (loss)		(444	)		—
Net loss reclassified into interest expense		31			—
Ending unrealized net loss in AOCL	$	(413	)	$	—

Derivative Financial Instruments - Schedule of Pretax Amounts Recognized in AOCL on Interest Rate Swap (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2022 USD ($)
Derivative Instruments, Gain (Loss) [Line Items]
Net loss recognized in other comprehensive income (loss)	$ (444)
Net loss reclassified into interest expense	31
Ending unrealized net loss in AOCL	$ (413)

Supplemental Balance Sheet Information

3 Months Ended

Dec. 31, 2022

Balance Sheet Related Disclosures [Abstract]

Supplemental Balance Sheet Information

5. Supplemental Balance Sheet Information

Inventories

Inventories consisted of the following components:


	December 31,		September 30,
(In thousands)	2022		2022
Raw materials	$	7,871	$	6,102
Work-in process		1,534		1,595
Finished products		3,319		4,122
Total	$	12,724	$	11,819

Prepaids and Other Assets, Current

Prepaids and other current assets consisted of the following:


	December 31,		September 30,
(In thousands)	2022		2022
Prepaid expenses	$	3,809	$	2,570
Irish research and development credits receivable		822		753
CARES Act employee retention credit receivable (1)		3,441		3,441
Prepaids and other	$	8,072	$	6,764

(1)

Receivable consisted of anticipated reimbursement of personnel expenses incurred in fiscal periods prior to fiscal 2023 as a result of our eligibility for the employee retention credit under the provisions of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act").

Intangible Assets

Intangible assets consisted of the following:


	December 31, 2022
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	12,291	$	(9,797	)	$	2,494
Developed technology		11.9		34,251		(9,110	)		25,141
Patents and other		14.1		3,551		(2,504	)		1,047
Total definite-lived intangible assets				50,093		(21,411	)		28,682
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total intangible assets			$	50,673	$	(21,411	)	$	29,262


	September 30, 2022
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	11,354	$	(8,827	)	$	2,527
Developed technology		11.9		31,943		(7,994	)		23,949
Patents and other		14.1		3,551		(2,462	)		1,089
Total definite-lived intangible assets				46,848		(19,283	)		27,565
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total intangible assets			$	47,428	$	(19,283	)	$	28,145

Intangible asset amortization expense was $1.0 million and $1.2 million for the three months ended December 31, 2022 and 2021, respectively. Based on the intangible assets in service as of December 31, 2022, estimated amortization expense for future fiscal years is as follows:


(In thousands)
Remainder of 2023	$	2,795
2024		3,726
2025		3,691
2026		2,806
2027		2,559
2028		2,548
Thereafter		10,557
Definite-lived intangible assets	$	28,682

Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, changes in amortization periods, foreign currency translation rates, or other factors.

Goodwill

Changes in the carrying amount of goodwill by segment were as follows:


(In thousands)	In Vitro Diagnostics		Medical Device		Total
Goodwill as of September 30, 2022	$	8,010	$	32,700	$	40,710
Currency translation adjustment		—		2,598		2,598
Goodwill as of December 31, 2022	$	8,010	$	35,298	$	43,308

Other Assets, Noncurrent

Other noncurrent assets consisted of the following:


	December 31,		September 30,
(In thousands)	2022		2022
Operating lease right-of-use assets	$	3,480	$	3,633
Other		1,526		1,136
Other assets	$	5,006	$	4,769

Other noncurrent assets consisted primarily of prepaid expenses and receivables related to refundable Irish research and development tax credits.

Accrued Other Liabilities

Accrued other liabilities consisted of the following:


	December 31,		September 30,
(In thousands)	2022		2022
Accrued professional fees	$	264	$	279
Accrued clinical study expense		1,903		1,425
Accrued purchases		1,562		1,655
Acquisition of in-process research and development (1)		1,933		981
Operating lease liability, current portion		1,027		963
Other		359		551
Total accrued other liabilities	$	7,048	$	5,854

(1)

Acquisition of in-process research and development consists of the present value of guaranteed payments to be made (current portion) in connection with an asset acquisition in fiscal 2018 (Note 11).

Other Long-term Liabilities

Other long-term liabilities consisted of the following:


	December 31,		September 30,
(In thousands)	2022		2022
Deferred consideration (1)	$	3,361	$	4,260
Contingent consideration (2)		832		829
Unrecognized tax benefits (3)		1,741		1,841
Operating lease liabilities (4)		3,584		3,843
Other long-term liabilities	$	9,518	$	10,773

(1)

Deferred consideration consists of the present value of guaranteed payments to be made (noncurrent portion) in connection with the fiscal 2021 Vetex acquisition and with an asset acquisition in fiscal 2018 (Note 11).

(2)

Contingent consideration consists of the fair value of contingent consideration liabilities associated with the fiscal 2021 Vetex acquisition (Note 11).

(3)

Balance of unrecognized tax benefits (Note 10) includes accrued interest and penalties, if applicable.

(4)

Operating lease liabilities consist of the non-current portion of the net present value of future minimum lease payments, reduced by the discounted value of leasehold improvement incentives paid or payable to the Company.

Stock-based Compensation Plans

3 Months Ended

Dec. 31, 2022

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based Compensation Plans

. Stock-based Compensation Plans

The Company has stock-based compensation plans approved by its shareholders under which it grants stock options, restricted stock awards, restricted stock units and deferred stock units to officers, directors and key employees. Stock-based compensation expense was reported as follows in the condensed consolidated statements of operations:


	Three Months Ended
	December 31,
(In thousands)	2022		2021
Product costs	$	67	$	30
Research and development		374		453
Selling, general and administrative		1,524		1,197
Total	$	1,965	$	1,680

As of December 31, 2022, unrecognized compensation costs related to non-vested awards totaled approximately $16.3 million, which is expected to be recognized over a weighted average period of approximately 2.7 years.

Stock Option Awards

The Company awards stock options to officers, directors and key employees and uses the Black-Scholes option pricing model to determine the fair value of stock options as of the date of each grant. Stock option grant activity was as follows:


	Three Months Ended December 31,
	2022		2021
Stock option grant activity:
Stock options granted		269,000		245,000
Weighted average grant date fair value	$	15.53	$	16.36
Weighted average exercise price	$	35.97	$	43.93

Restricted Stock Awards

During the three months ended December 31, 2022 and 2021, the Company awarded 99,000 and 78,000 restricted stock shares, respectively, to certain key employees and officers with a weighted average grant date fair value per share of $36.05 and $43.93, respectively. Restricted Stock is valued based on the market value of the shares as of the date of grant.

Restricted Stock Unit Awards

During each of the three months ended December 31, 2022 and 2021, the Company awarded 6,000 restricted stock units (“RSUs”) to directors and to key employees in foreign jurisdictions with a weighted average grant date fair value per unit of $36.13 and $43.93, respectively. RSUs are valued based on the market value of the shares as of the date of grant.

Employee Stock Purchase Plan

Our U.S. employees are eligible to participate in the amended 1999 Employee Stock Purchase Plan (“ESPP”) approved by our shareholders. During the three months ended December 31, 2022 and 2021, no shares were issued under the ESPP, respectively.

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022
Statement Of Financial Position [Abstract]
Allowances (accounts receivable)	$ 140	$ 81
Series A preferred stock, par value	$ 0.05	$ 0.05
Series A preferred stock, shares authorized	450,000	450,000
Series A preferred stock, shares issued	0	0
Series A preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	14,126,000	14,029,000
Common stock, shares outstanding	14,126,000	14,029,000

Revenue

3 Months Ended

Dec. 31, 2022

Revenue From Contract With Customer [Abstract]

Revenue

2. Revenue

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.


	Three Months Ended December 31,
(In thousands)	2022		2021
Medical Device
Product sales	$	8,380	$	6,788
Royalties		7,409		6,886
License fees		1,356		1,213
Research, development and other		1,873		2,021
Medical Device Revenue		19,018		16,908
In Vitro Diagnostics
Product sales		5,854		5,556
Research, development and other		61		539
In Vitro Diagnostics Revenue		5,915		6,095
Total Revenue	$	24,933	$	23,003

Contract assets totaled $7.0 million and $7.1 million as of December 31, 2022 and September 30, 2022, respectively, on the condensed consolidated balance sheets. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected, at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangement.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Subsequent Events

3 Months Ended

Dec. 31, 2022

Subsequent Events [Abstract]

Subsequent Events

13. Subsequent Events

In the second quarter of fiscal 2023, we initiated certain organizational changes to reduce our use of cash by reducing the Company's workforce by approximately 13%, primarily in our Medical Device segment. We expect to incur $1.0 million to $1.2 million of pre-tax restructuring expense for severance and related charges in the second quarter of fiscal 2023. The workforce reduction is expected to be completed, including the majority of cash paid, within the second quarter of fiscal 2023.

Segment Information (Tables)

3 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Segment Revenue, Operating Loss and Depreciation and Amortization

Segment revenue, operating loss, and depreciation and amortization were as follows:


	Three Months Ended
	December 31,
(In thousands)	2022			2021
Revenue:
Medical Device	$	19,018		$	16,908
In Vitro Diagnostics		5,915			6,095
Total revenue	$	24,933		$	23,003

Operating (loss) income:
Medical Device	$	(7,235	)	$	(3,792	)
In Vitro Diagnostics		2,948			3,155
Total segment operating (loss) income		(4,287	)		(637	)
Corporate		(2,942	)		(2,804	)
Total operating (loss) income	$	(7,229	)	$	(3,441	)

Depreciation and amortization:
Medical Device	$	1,953		$	2,194
In Vitro Diagnostics		77			86
Corporate		92			96
Total depreciation and amortization	$	2,122		$	2,376

Fair Value Measurements

3 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

Assets and liabilities measured at fair value on a recurring basis by level of the fair value hierarchy were as follows:


	December 31, 2022
(In thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
Assets
Cash equivalents (1)	$	—	$	17,134	$	—	$	17,134
Total assets	$	—	$	17,134	$	—	$	17,134

Liabilities
Contingent consideration (2)	$	—	$	—	$	832	$	832
Interest rate swap (3)		—		413		—		413
Total liabilities	$	—	$	413	$	832	$	1,245



	September 30, 2022
(In thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
Assets
Cash equivalents (1)	$	—	$	2,035	$	—	$	2,035
Total assets	$	—	$	2,035	$	—	$	2,035

Liabilities
Contingent consideration (2)	$	—	$	—	$	829	$	829

(1)

Fair value of cash equivalents (money market funds) is based on quoted vendor prices and broker pricing where all significant inputs are observable.

(2)

Fair value of contingent consideration liabilities was determined based on discounted cash flow analyses that included probability and timing of development and regulatory milestone achievements and a discount rate, which are considered significant unobservable inputs as of both December 31, 2022 and September 30, 2022.

(3)

Fair value of interest rate swap is based on forward-looking, one-month term secured overnight financing rate (“Term SOFR”) spot rates and interest rate curves (Note 7).

Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment and projected payment dates. Increases or decreases in the fair value of the contingent consideration liability can result from changes in the timing or likelihood of achieving milestones and changes in discount periods and rates. Projected contingent payment amounts are discounted back to the current period using a discount cash flow model. Interest accretion and fair value adjustments associated with contingent consideration liabilities are reported in contingent consideration expense (gain) on the condensed consolidated statements of operations.

Changes in the contingent consideration liabilities measured at fair value using Level 3 inputs were as follows:


(In thousands)
Contingent consideration liability at September 30, 2022	$	829
Additions		—
Fair value adjustments		—
Settlements		—
Interest accretion		3
Foreign currency translation		—
Contingent consideration liability at December 31, 2022	$	832

Contingent consideration liabilities were associated with the fiscal 2021 acquisition of Vetex Medical Limited ("Vetex") and were included in other long-term liabilities on the condensed consolidated balance sheets.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Net Loss Per Share Data - Additional Information (Detail) - shares shares in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0.1	0.2

Supplemental Balance Sheet Information (Tables)

3 Months Ended

Dec. 31, 2022

Balance Sheet Related Disclosures [Abstract]

Components of Inventories

Inventories consisted of the following components:


	December 31,		September 30,
(In thousands)	2022		2022
Raw materials	$	7,871	$	6,102
Work-in process		1,534		1,595
Finished products		3,319		4,122
Total	$	12,724	$	11,819

Summary of Prepaids and Other Current Assets

Prepaids and other current assets consisted of the following:


	December 31,		September 30,
(In thousands)	2022		2022
Prepaid expenses	$	3,809	$	2,570
Irish research and development credits receivable		822		753
CARES Act employee retention credit receivable (1)		3,441		3,441
Prepaids and other	$	8,072	$	6,764

(1)

Schedule of Intangible Assets

Intangible assets consisted of the following:


	December 31, 2022
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	12,291	$	(9,797	)	$	2,494
Developed technology		11.9		34,251		(9,110	)		25,141
Patents and other		14.1		3,551		(2,504	)		1,047
Total definite-lived intangible assets				50,093		(21,411	)		28,682
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total intangible assets			$	50,673	$	(21,411	)	$	29,262


	September 30, 2022
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	11,354	$	(8,827	)	$	2,527
Developed technology		11.9		31,943		(7,994	)		23,949
Patents and other		14.1		3,551		(2,462	)		1,089
Total definite-lived intangible assets				46,848		(19,283	)		27,565
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total intangible assets			$	47,428	$	(19,283	)	$	28,145

Estimated Amortization Expense

Based on the intangible assets in service as of December 31, 2022, estimated amortization expense for future fiscal years is as follows:


(In thousands)
Remainder of 2023	$	2,795
2024		3,726
2025		3,691
2026		2,806
2027		2,559
2028		2,548
Thereafter		10,557
Definite-lived intangible assets	$	28,682

Schedule of Carrying Amount of Goodwill By Reportable Segment

Changes in the carrying amount of goodwill by segment were as follows:


(In thousands)	In Vitro Diagnostics		Medical Device		Total
Goodwill as of September 30, 2022	$	8,010	$	32,700	$	40,710
Currency translation adjustment		—		2,598		2,598
Goodwill as of December 31, 2022	$	8,010	$	35,298	$	43,308

Summary of Other Noncurrent Assets

Other noncurrent assets consisted of the following:


	December 31,		September 30,
(In thousands)	2022		2022
Operating lease right-of-use assets	$	3,480	$	3,633
Other		1,526		1,136
Other assets	$	5,006	$	4,769

Schedule of Accrued Other Liabilities

Accrued other liabilities consisted of the following:


	December 31,		September 30,
(In thousands)	2022		2022
Accrued professional fees	$	264	$	279
Accrued clinical study expense		1,903		1,425
Accrued purchases		1,562		1,655
Acquisition of in-process research and development (1)		1,933		981
Operating lease liability, current portion		1,027		963
Other		359		551
Total accrued other liabilities	$	7,048	$	5,854

(1)

Acquisition of in-process research and development consists of the present value of guaranteed payments to be made (current portion) in connection with an asset acquisition in fiscal 2018 (Note 11).

Schedule of Other Long-term Liabilities

Other long-term liabilities consisted of the following:


	December 31,		September 30,
(In thousands)	2022		2022
Deferred consideration (1)	$	3,361	$	4,260
Contingent consideration (2)		832		829
Unrecognized tax benefits (3)		1,741		1,841
Operating lease liabilities (4)		3,584		3,843
Other long-term liabilities	$	9,518	$	10,773

(1)

(2)

Contingent consideration consists of the fair value of contingent consideration liabilities associated with the fiscal 2021 Vetex acquisition (Note 11).

(3)

Balance of unrecognized tax benefits (Note 10) includes accrued interest and penalties, if applicable.

(4)

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Organization (Policies)	3 Months Ended
Organization (Policies)	Dec. 31, 2022
Accounting Policies [Abstract]
Business Description and Basis of Presentation [Text Block]	Description of Business Surmodics, Inc. and subsidiaries (referred to as “Surmodics,” the “Company,” “we,” “us,” “our” and other like terms) is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (“IVD”) immunoassay tests and microarrays. Surmodics develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development and manufacturing capabilities. The Company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include all accounts and wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). All intercompany transactions have been eliminated. The Company operates on a fiscal year ending on September 30. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2022, and notes thereto included in our Annual Report on Form 10-K as filed with the SEC.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. The results of operations for the three months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the entire 2023 fiscal year. Certain reclassifications have been made to the prior year's consolidated financial statements to conform to the current year presentation.
New Accounting Pronouncements	New Accounting Pronouncements No new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.
Net Loss Per Share Data	Basic net loss per common share is calculated by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options and non-vested stock relating to restricted stock awards and restricted stock units. For the three months ended December 31, 2022 and 2021, 0.1 million and 0.2 million in weighted-average shares, respectively, were excluded from the calculation of diluted net loss per share as their effect was anti-dilutive as a result of the net loss incurred for those periods. Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended December 31, 2022 and 2021.
Income Taxes	For interim income tax reporting, the Company estimates its annual effective tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded.
Income Tax Uncertainties	The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions, as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. The Internal Revenue Service commenced an examination of the Company’s fiscal 2019 U.S. federal tax return in fiscal 2022; the examination has not been completed. U.S. federal income tax returns for years prior to fiscal 2019 are no longer subject to examination by federal tax authorities. For tax returns for U.S. state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2012. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2018. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical, Ltd.; NorMedix, Inc.; and Vetex for periods prior to the respective acquisition dates, pursuant to the terms of the related share purchase agreements.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

Net Loss Per Share Data - Denominator for Computation of Diluted Weighted Average Shares Outstanding (Detail) - shares shares in Thousands	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Basic weighted average shares outstanding	13,983	13,878
Diluted weighted average shares outstanding	13,983	13,878

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Member] - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 17,134	$ 2,035
Liabilities measured at fair value	1,245
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	17,134	2,035
Liabilities measured at fair value	413
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	832
Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	17,134	2,035
Cash equivalents [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	17,134	2,035
Contingent consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	832	829
Contingent consideration [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	832	$ 829
Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	413
Interest Rate Swap [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	$ 413

Debt

3 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Debt

6. Debt

Debt consisted of the following:


	December 31,			September 30,
(In thousands)	2022			2022
Short-term borrowings (1)	$	—		$	10,000

Revolving Credit Facility, Term SOFR + 3.00%, maturing October 1, 2027	$	5,000		$	—
Tranche 1 Term Loans, Term SOFR +5.75%, maturing October 1, 2027		25,000			—
Long-term debt, gross		30,000			—
Less: Unamortized debt issuance costs		(505	)		—
Long-term debt, net	$	29,495		$	—

(1)

Consisted of the outstanding balance on the secured revolving credit facility with Bridgewater Bank; this balance was repaid and the credit agreement terminated on October 14, 2022. For further information, refer to the Notes to the Consolidated Financial Statements in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended September 30, 2022.

On October 14, 2022, the Company entered into a secured revolving credit facility and secured term loan facilities pursuant to a Credit, Security and Guaranty Agreement (the “MidCap Credit Agreement”) with Mid Cap Funding IV Trust, as agent, and MidCap Financial Trust, as term loan servicer and the lenders from time to time party thereto. The MidCap Credit Agreement provides for availability under a secured revolving line of credit of up to $25.0 million (the “Revolving Credit Facility”), and proceeds may be used for transaction fees and for working capital needs and general corporate purposes. Availability under the Revolving Credit Facility is subject to a borrowing base.

The MidCap Credit Agreement also provides for up to $75.0 million in term loans (the “Term Loans”), consisting of a $25.0 million Tranche 1 (“Tranche 1”) and a $50.0 million Tranche 2 (“Tranche 2”), which may be drawn in increments of at least $10.0 million. In addition, after the closing and prior to December 31, 2024, the Term Loan lenders may, in their sole discretion, fund an additional tranche of Term Loans of up to $25.0 million upon the written request of the Company. Upon closing, the Company borrowed $25.0 million of Tranche 1, borrowed $5.0 million on the Revolving Credit Facility, and used approximately $10.0 million of the proceeds to repay borrowings under the revolving credit facility with Bridgewater Bank, and intends to use the remaining proceeds to fund working capital needs and other general corporate purposes. Until December 31, 2024, the Company will be eligible to borrow Tranche 2 at the Company’s option upon meeting certain conditions set forth in the MidCap Credit Agreement, including having no less than $60.0 million of rolling-four-quarter core net revenue as of the end of the prior fiscal quarter. Core net revenue is defined in the MidCap Credit Agreement as the sum of revenue from our In Vitro Diagnostics segment and revenues from performance coating technologies in our Medical Device segment.

Pursuant to the MidCap Credit Agreement, the Company provided a first priority security interest in all existing and future acquired assets, including intellectual property and real estate, owned by the Company. The MidCap Credit Agreement contains certain covenants that limit the Company’s ability to engage in certain transactions. Subject to certain limited exceptions, these covenants limit the Company’s ability to, among other things:

•

create, incur, assume or permit to exist any additional indebtedness, or create, incur, allow or permit to exist any additional liens;

•

enter into any amendment or other modification of certain agreements;

•

effect certain changes in the Company’s business, fiscal year, management, entity name or business locations;

•

liquidate or dissolve, merge with or into, or consolidate with, any other company;

•

pay cash dividends on, make any other distributions in respect of, or redeem, retire or repurchase, any shares of the Company’s capital stock;

•

make certain investments, other than limited permitted acquisitions; and

•

enter into transactions with the Company’s affiliates.

The MidCap Credit Agreement also contains customary indemnification obligations and customary events of default, including, among other things, (i) non-payment, (ii) breach of warranty, (iii) non-performance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) termination of a pension plan, (x) regulatory matters, and (xi) material adverse effect.

In addition, the Company must maintain minimum core net revenue levels tested quarterly to the extent that Term Loans advanced under the MidCap Credit Agreement exceed $25.0 million. In the event of default under the MidCap Credit Agreement, the Company would be required to pay interest on principal and all other due and unpaid obligations at the current rate in effect plus 2%.

Borrowings under the MidCap Credit Agreement bear interest at the forward-looking, one-month secured overnight financing rate (“Term SOFR”) as published by CME Group Benchmark Administration Limited plus 0.10% (“Adjusted Term SOFR”). The Revolving Credit Facility bears interest at an annual rate equal to 3.00% plus the greater of Adjusted Term SOFR or 1.50%, and the Term Loans bear interest at an annual rate equal to 5.75% plus the greater of Adjusted Term SOFR or 1.50%. The Company is required to make monthly interest payments on the Revolving Credit Facility with the entire principal payment due at maturity. The Company is required to make 48 monthly interest payments on the Term Loans beginning on November 1, 2022 (the “Interest-Only Period”). If the Company is in covenant compliance at the end of the Interest-Only Period, the Company will have the option to extend the Interest-Only Period through maturity with the entire principal payment due at maturity. If the Company is not in covenant compliance at the end of the Interest-Only Period, the Company is required to make 12 months of straight-line amortization payments with the entire principal amount due at maturity.

Subject to certain limitations, the Term Loans have a prepayment fee for payments made prior to the maturity date equal to 3.0% of the prepaid principal amount for the first year following the closing date of the MidCap Credit Agreement, 2.0% of the prepaid principal amount for the second year following the closing date and 1.0% of the prepaid principal amount for the third year following the closing date and thereafter. In addition, if the Revolving Credit Facility is terminated in whole or in part prior to the maturity date, the Company must pay a prepayment fee equal to 3.0% of the terminated commitment amount for the first year following the closing date of the MidCap Credit Agreement, 2.0% of the terminated commitment amount for the second year following the closing date of the MidCap Credit Agreement and 1.0% of the terminated commitment amount for the third year following the closing date and thereafter. The Company is also required to pay a full exit fee at the time of maturity or full prepayment event equal to 2.5% of the aggregate principal amount of the Term Loans made pursuant to the MidCap Credit Agreement and a partial exit fee at the time of any partial prepayment event equal to 2.5% of the amount prepaid. This exit fee is accreted over the remaining term of the Term Loans. The Company also is obligated to pay customary origination fees at the time of each funding of the Term Loans and a customary annual administrative fee based on the amount borrowed under the Term Loan, due on an annual basis. The customary fees on the Revolving Credit Facility include (i) an origination fee based on the commitment amount, which was paid on the closing date, (ii) an annual collateral management fee of 0.50% per annum based on the outstanding balance of the Revolving Credit Facility, payable monthly in arrears and (iii) an unused line fee of 0.50% per annum based on the average unused portion of the Revolving Credit Facility, payable monthly in arrears. The Company must also maintain a minimum balance of no less than 20% of availability under the Revolving Credit Facility or a minimum balance fee applies of 0.50% per annum. Expenses recognized for fees for the Revolving Credit Facility and Term Loans are reported in interest expense, net on the condensed consolidated statements of operations.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Derivative Financial Instruments (Tables)

3 Months Ended

Dec. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Net Fair Value of Designated Hedge Derivatives Subject to Master Netting Arrangements Reported on Condensed Consolidated Balance Sheets

The net fair value of designated hedge derivatives subject to master netting arrangements reported on the condensed consolidated balance sheets was as follows:


	Asset (Liability)
(In thousands)	Gross Recognized Amount			Gross Offset Amount		Net Amount Presented			Cash Collateral Receivable		Net Amount Reported		Balance Sheet Location
December 31, 2022
Interest rate swap	$	(413	)	$	—	$	(413	)	$	533	$	120	Other assets, noncurrent
September 30, 2022
—	$	—		$	—	$	—		$	—	$	—	—

Schedule of Pretax Amounts Recognized in AOCL on Interest Rate Swap

The pretax amounts recognized in AOCL on the interest rate swap were as follows:


	Three Months Ended December 31,
(In thousands)	2022			2021
Beginning unrealized net loss in AOCL	$	—		$	—
Net loss recognized in other comprehensive income (loss)		(444	)		—
Net loss reclassified into interest expense		31			—
Ending unrealized net loss in AOCL	$	(413	)	$	—

Debt - Schedule of Debt (Parenthetical) (Detail) - Term SOFR [Member]	3 Months Ended
	Dec. 31, 2022
Revolving Credit Facility, Term SOFR + 3.00%, Maturing October 1, 2027 [Member]
Schedule of Debt [Line Items]
Description of variable rate basis	Term SOFR + 3.00%
Debt instrument, basis spread on variable rate	3.00%
Maturity date	Oct. 01, 2027
Tranche 1 Term Loans, Term SOFR +5.75%, Maturing October 1, 2027 [Member]
Schedule of Debt [Line Items]
Description of variable rate basis	Term SOFR +5.75%
Debt instrument, basis spread on variable rate	5.75%
Maturity date	Oct. 01, 2027

Debt - Additional Information (Detail) - USD ($)		3 Months Ended
Debt - Additional Information (Detail) - USD ($)	Oct. 14, 2022	Dec. 31, 2022	Sep. 30, 2022
Line Of Credit Facility [Line Items]
Secured term loan facilities, proceeds at closing		$ 30,000,000
Revolving credit facility, outstanding balance			$ 10,000,000
MidCap Credit Agreement [Member] \| Secured Overnight Financing Rate [Member]
Line Of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	0.10%
Description of variable rate basis		one-month secured overnight financing rate (“Term SOFR”) as published by CME Group Benchmark Administration Limited plus 0.10%
MidCap Credit Agreement [Member] \| Term Loans [Member]
Line Of Credit Facility [Line Items]
Secured term loan facilities, borrowing capacity	$ 75,000,000.0
Debt instrument, basis spread on variable rate	5.75%
MidCap Credit Agreement, exit fee	2.50%
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Minimum [Member]
Line Of Credit Facility [Line Items]
Secured term loan facilities, borrowing capacity	$ 10,000,000.0
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Minimum [Member] \| Secured Overnight Financing Rate [Member]
Line Of Credit Facility [Line Items]
Debt instrument, variable rate floor	1.50%
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Minimum [Member] \| Rolling-four-quarter Core Net Revenue [Member]
Line Of Credit Facility [Line Items]
MidCap Credit Agreement, minimum rolling-four-quarter core net revenue	$ 60,000,000.0
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Tranche 1 [Member]
Line Of Credit Facility [Line Items]
Secured term loan facilities, borrowing capacity	25,000,000.0
Secured term loan facilities, proceeds at closing	25,000,000.0
Repayments of lines of credit	10,000,000.0
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Tranche 2 [Member]
Line Of Credit Facility [Line Items]
Secured term loan facilities, borrowing capacity	50,000,000.0
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Tranche 2 [Member] \| Minimum [Member] \| Rolling-four-quarter Core Net Revenue [Member]
Line Of Credit Facility [Line Items]
Secured term loan facilities, borrowing capacity	25,000,000.0
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Additional Tranche [Member] \| Maximum [Member]
Line Of Credit Facility [Line Items]
Secured term loan facilities, borrowing capacity	$ 25,000,000.0
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Midcap Event Of Default [Member] \| Midcap Revolving Credit Facility [Member]
Line Of Credit Facility [Line Items]
MidCap Credit Agreement, interest rate premium upon event of default	2.00%
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Year One [Member]
Line Of Credit Facility [Line Items]
Prepayment penalty	3.00%
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Year Two [Member]
Line Of Credit Facility [Line Items]
Prepayment penalty	2.00%
MidCap Credit Agreement [Member] \| Term Loans [Member] \| Year Three [Member]
Line Of Credit Facility [Line Items]
Prepayment penalty	1.00%
MidCap Credit Agreement [Member] \| Revolving Credit Facility [Member]
Line Of Credit Facility [Line Items]
Revolving credit facility, maximum borrowing capacity	$ 25,000,000.0
Debt instrument, basis spread on variable rate	3.00%
Revolving credit facility, minimum borrowing as percentage of availability	20.00%
Percentage of annual collateral management fee	0.50%
Percentage of annual unused line fee	0.50%
Percentage of annual minimum balance fee	0.50%
MidCap Credit Agreement [Member] \| Revolving Credit Facility [Member] \| Minimum [Member] \| Secured Overnight Financing Rate [Member]
Line Of Credit Facility [Line Items]
Debt instrument, variable rate floor	1.50%
MidCap Credit Agreement [Member] \| Revolving Credit Facility [Member] \| Tranche 1 [Member]
Line Of Credit Facility [Line Items]
Revolving credit facility, proceeds at closing	$ 5,000,000.0
MidCap Credit Agreement [Member] \| Revolving Credit Facility [Member] \| Year One [Member]
Line Of Credit Facility [Line Items]
Prepayment penalty	3.00%
MidCap Credit Agreement [Member] \| Revolving Credit Facility [Member] \| Year Two [Member]
Line Of Credit Facility [Line Items]
Prepayment penalty	2.00%
MidCap Credit Agreement [Member] \| Revolving Credit Facility [Member] \| Year Three [Member]
Line Of Credit Facility [Line Items]
Prepayment penalty	1.00%

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022
Revenue From Contract With Customer [Abstract]
Contract assets — royalties and license fees	$ 7,047	$ 7,116

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022
Income Tax Disclosure [Line Items]
Income tax benefit	$ 165,000	$ 706,000
U.S. federal statutory tax rate	21.00%
Discrete tax benefits related to stock-based compensation awards	$ 100,000	$ 100,000
Unrecognized tax benefits excluding interest and penalties that would impact effective tax rate	3,000,000.0		$ 2,500,000
Undistributed earnings in foreign subsidiaries	$ 0		$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Supplemental Balance Sheet Information - Estimated Amortization Expense (Detail) $ in Thousands	Dec. 31, 2022 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2023	$ 2,795
2024	3,726
2025	2,806
2026	3,691
2027	2,559
2028	2,548
Thereafter	10,557
Definite-lived intangible assets, Net	$ 28,682

Fair Value Measurements (Tables)

3 Months Ended

Dec. 31, 2022

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on Recurring Basis

Assets and liabilities measured at fair value on a recurring basis by level of the fair value hierarchy were as follows:


	December 31, 2022
(In thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
Assets
Cash equivalents (1)	$	—	$	17,134	$	—	$	17,134
Total assets	$	—	$	17,134	$	—	$	17,134

Liabilities
Contingent consideration (2)	$	—	$	—	$	832	$	832
Interest rate swap (3)		—		413		—		413
Total liabilities	$	—	$	413	$	832	$	1,245



	September 30, 2022
(In thousands)	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value
Assets
Cash equivalents (1)	$	—	$	2,035	$	—	$	2,035
Total assets	$	—	$	2,035	$	—	$	2,035

Liabilities
Contingent consideration (2)	$	—	$	—	$	829	$	829

(1)

Fair value of cash equivalents (money market funds) is based on quoted vendor prices and broker pricing where all significant inputs are observable.

(2)

(3)

Fair value of interest rate swap is based on forward-looking, one-month term secured overnight financing rate (“Term SOFR”) spot rates and interest rate curves (Note 7).

Schedule of Contingent Consideration Liabilities Measured at Fair Value

Changes in the contingent consideration liabilities measured at fair value using Level 3 inputs were as follows:


(In thousands)
Contingent consideration liability at September 30, 2022	$	829
Additions		—
Fair value adjustments		—
Settlements		—
Interest accretion		3
Foreign currency translation		—
Contingent consideration liability at December 31, 2022	$	832

Stock-based Compensation Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Stock-Based Compensation Activity [Line Items]
Unrecognized compensation costs, nonvested awards, amount	$ 16.3
Unrecognized compensation costs, nonvested awards, weighted average recognition period	2 years 8 months 12 days
Restricted Stock Awards [Member]
Stock-Based Compensation Activity [Line Items]
Units granted	99,000	78,000
Weighted average grant date fair value	$ 36.05	$ 43.93
Restricted Stock Unit Awards [Member]
Stock-Based Compensation Activity [Line Items]
Units granted	6,000	6,000
Weighted average grant date fair value	$ 36.13	$ 43.93
Employee Stock Purchase Plan [Member]
Stock-Based Compensation Activity [Line Items]
Shares issued	0	0

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (7,843)	$ (2,812)
Derivative instruments:
Unrealized net loss	(444)
Net loss reclassified to earnings	31
Net changes related to available-for-sale securities, net of tax		(5)
Foreign currency translation adjustments	5,670	(1,647)
Other comprehensive income (loss)	5,257	(1,652)
Comprehensive loss	$ (2,586)	$ (4,464)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

Debt - Schedule of Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022
Schedule of Debt [Line Items]
Short-term borrowings		$ 10,000
Long-term debt, gross	$ 30,000
Less: Unamortized debt issuance costs	(505)
Long-term debt, net	29,495
Revolving Credit Facility, Term SOFR + 3.00%, Maturing October 1, 2027 [Member] \| Term SOFR [Member]
Schedule of Debt [Line Items]
Long-term debt, gross	5,000
Tranche 1 Term Loans, Term SOFR +5.75%, Maturing October 1, 2027 [Member] \| Term SOFR [Member]
Schedule of Debt [Line Items]
Long-term debt, gross	$ 25,000

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Supplemental Balance Sheet Information - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Amortization expense	$ 1.0	$ 1.2

Supplemental Balance Sheet Information - Summary of Prepaids and Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022
Prepaid Expense And Other Assets Current [Abstract]
Prepaid expenses	$ 3,809	$ 2,570
Irish research and development credits receivable	822	753
CARES Act employee retention credit receivable	3,441	3,441
Prepaids and other	$ 8,072	$ 6,764

Commitments and Contingencies

3 Months Ended

Dec. 31, 2022

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

11. Commitments and Contingencies

Clinical Trials. The Company has engaged clinical trial clinical research organization (“CRO”) consultants to assist with the administration of its ongoing clinical trials. The Company has executed separate contracts with two CROs for services rendered in connection with the TRANSCEND pivotal clinical trial for the SurVeil DCB, including pass-through expenses paid by the CROs, of up to approximately $30 million in the aggregate. As of December 31, 2022, an estimated $5 million remains to be paid on these contracts, which may vary depending on actual pass-through expenses incurred to execute the trial. The Company estimates that the total cost of the TRANSCEND clinical trial will be in the range of $37 million to $40 million from inception to completion. In the event the Company were to terminate any trial, it may incur certain financial penalties which would become payable to the CRO for costs to wind down the terminated trial.

Asset Acquisitions. In fiscal 2018, the Company acquired certain intellectual property assets of Embolitech, LLC (the “Embolitech Transaction”). As part of the Embolitech Transaction, the Company paid the sellers $5.0 million in fiscal 2018, $1.0 million in fiscal 2020, $1.0 million in fiscal 2021, and $0.5 million in fiscal 2022. The Company is obligated to pay additional installments totaling $2.0 million in fiscal 2023 through fiscal 2024. These payments may be accelerated upon the occurrence of certain sales and regulatory milestones. An additional $1.0 million payment is contingent upon the achievement of certain regulatory milestones within a contingency period ending in 2033.

Vetex Acquisition. In fiscal 2021, Surmodics acquired all of the outstanding shares of Vetex with an upfront cash payment of $39.9 million. The Company is obligated to pay additional installments totaling $3.5 million in fiscal 2024 through fiscal 2027. These payments may be accelerated upon the occurrence of certain product development and regulatory milestones. An additional $3.5 million in payments is contingent upon the achievement of certain product development and regulatory milestones within a contingency period ending in fiscal 2027.

Derivative Financial Instruments - Additional Information (Detail) - Term Loans [Member] $ in Millions	3 Months Ended
	Dec. 31, 2022 USD ($)
Derivative [Line Items]
Notional amount	$ 25
Fixed interest	10.205%
Interest Rate Swap [Member]
Derivative [Line Items]
Notional amount	$ 25
Expiry date	Oct. 01, 2027
Fixed interest	4.455%

Derivative Financial Instruments - Schedule of Net Fair Value of Designated Hedge Derivatives Subject to Master Netting Arrangements Reported on Condensed Consolidated Balance Sheets (Detail) - Interest Rate Swap [Member] $ in Thousands	Dec. 31, 2022 USD ($)
Offsetting Assets [Line Items]
Gross Recognized Amount	$ (413)
Net Amount Presented	(413)
Cash Collateral Receivable	533
Net Amount Reported	$ 120
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets Noncurrent

Stock-based Compensation Plans - Summary of Stock Option Grant Activity (Detail) - Stock Option Awards [Member] - $ / shares	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock options granted	269,000	245,000
Weighted average grant date fair value	$ 15.53	$ 16.36
Weighted average exercise price	$ 35.97	$ 43.93

Collaborative Arrangement - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue	$ 24,933,000	$ 23,003,000
Deferred revenue							$ 9,200,000
Abbott Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement payment received	60,800,000
Total revenue	1,300,000	1,200,000
Collaboration revenue recognized included in balance at beginning of period	1,300,000	$ 1,200,000
Deferred revenue	7,900,000
Abbott Agreement [Member] \| Upfront Payment [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement payment received						$ 25,000,000
Abbott Agreement [Member] \| Milestone Payment [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement payment received			$ 15,000,000	$ 10,800,000	$ 10,000,000
Abbott Agreement [Member] \| PMA Received After December 31, 2022 [Member] \| TRANSCEND Clinical Trial [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement additional potential milestone payments receivable	$ 24,000,000

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022
Current Assets:
Cash and cash equivalents	$ 26,430	$ 18,998
Accounts receivable, net of allowances of $140 and $81 as of December 31, 2022 and September 30, 2022, respectively	10,068	10,452
Contract assets — royalties and license fees	7,047	7,116
Inventories, net	12,724	11,819
Income tax receivable	121	2,438
Prepaids and other	8,072	6,764
Total Current Assets	64,462	57,587
Property and equipment, net	27,717	27,148
Intangible assets, net	29,262	28,145
Goodwill	43,308	40,710
Other assets	5,006	4,769
Total Assets	169,755	158,359
Current Liabilities:
Accounts payable	2,035	3,136
Accrued liabilities:
Compensation	4,410	8,929
Accrued other	7,048	5,854
Short-term borrowings		10,000
Deferred revenue	3,771	4,160
Total Current Liabilities	17,264	32,079
Long-term debt, net	29,495
Deferred revenue, less current portion	4,115	5,088
Deferred income taxes	2,102	2,027
Other long-term liabilities	9,518	10,773
Total Liabilities	62,494	49,967
Commitments and Contingencies (Note 11)
Stockholders’ Equity:
Series A Preferred stock — $.05 par value, 450 shares authorized; no shares issued and outstanding
Common stock - $.05 par value, 45,000 shares authorized;14126 and 14029 shares issued and outstanding as of December 31, 2022 and September 30, 2022, respectively	706	701
Additional paid-in capital	30,224	28,774
Accumulated other comprehensive loss	(4,617)	(9,874)
Retained earnings	80,948	88,791
Total Stockholders’ Equity	107,261	108,392
Total Liabilities and Stockholders’ Equity	$ 169,755	$ 158,359

Supplemental Balance Sheet Information - Schedule of Carrying Amount of Goodwill by Segment (Detail) $ in Thousands	3 Months Ended
	Dec. 31, 2022 USD ($)
Goodwill [Line Items]
Goodwill as of September 30, 2022	$ 40,710
Currency translation adjustment	2,598
Goodwill as of December 31, 2022	43,308
In Vitro Diagnostics [Member]
Goodwill [Line Items]
Goodwill as of September 30, 2022	8,010
Goodwill as of December 31, 2022	8,010
Medical Device [Member]
Goodwill [Line Items]
Goodwill as of September 30, 2022	32,700
Currency translation adjustment	2,598
Goodwill as of December 31, 2022	$ 35,298

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Supplemental Balance Sheet Information - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022
Intangible Assets [Line Items]
Definite-lived intangible assets, Accumulated Amortization	$ (21,411)	$ (19,283)
Definite-lived intangible assets, Net	28,682
Intangible assets, Gross Carrying Amount	50,673	47,428
Intangible assets, Net	$ 29,262	$ 28,145
Customer Lists and Relationships [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years 10 months 24 days	8 years 10 months 24 days
Definite-lived intangible assets, Gross Carrying Amount	$ 12,291	$ 11,354
Definite-lived intangible assets, Accumulated Amortization	(9,797)	(8,827)
Definite-lived intangible assets, Net	$ 2,494	$ 2,527
Developed Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	11 years 10 months 24 days	11 years 10 months 24 days
Definite-lived intangible assets, Gross Carrying Amount	$ 34,251	$ 31,943
Definite-lived intangible assets, Accumulated Amortization	(9,110)	(7,994)
Definite-lived intangible assets, Net	$ 25,141	$ 23,949
Patents and Other [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	14 years 1 month 6 days	14 years 1 month 6 days
Definite-lived intangible assets, Gross Carrying Amount	$ 3,551	$ 3,551
Definite-lived intangible assets, Accumulated Amortization	(2,504)	(2,462)
Definite-lived intangible assets, Net	1,047	1,089
Definite-Lived Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Gross Carrying Amount	50,093	46,848
Definite-lived intangible assets, Accumulated Amortization	(21,411)	(19,283)
Definite-lived intangible assets, Net	28,682	27,565
Trademarks and Trade Names [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	$ 580	$ 580

Supplemental Balance Sheet Information - Components of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 7,871	$ 6,102
Work-in process	1,534	1,595
Finished products	3,319	4,122
Total	$ 12,724	$ 11,819

Fair Value Measurements - Schedule of Contingent Consideration Liabilities Measured at Fair Value (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Interest accretion	$ 3	$ 3
Contingent Consideration [Member] \| Significant Unobservable Inputs (Level 3) [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Contingent consideration liability, beginning balance	829
Interest accretion	3
Contingent consideration liability, ending balance	$ 832

Organization	3 Months Ended
Organization	Dec. 31, 2022
Accounting Policies [Abstract]
Organization	1. Organization Description of Business Surmodics, Inc. and subsidiaries (referred to as “Surmodics,” the “Company,” “we,” “us,” “our” and other like terms) is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (“IVD”) immunoassay tests and microarrays. Surmodics develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development and manufacturing capabilities. The Company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include all accounts and wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). All intercompany transactions have been eliminated. The Company operates on a fiscal year ending on September 30. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2022, and notes thereto included in our Annual Report on Form 10-K as filed with the SEC. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. The results of operations for the three months ended December 31, 2022 are not necessarily indicative of the results that may be expected for the entire 2023 fiscal year. Certain reclassifications have been made to the prior year's consolidated financial statements to conform to the current year presentation. New Accounting Pronouncements No new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

Segment Information - Segment Revenue, Operating Loss and Depreciation and Amortization (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Revenue	$ 24,933	$ 23,003
Total operating (loss) income	(7,229)	(3,441)
Depreciation and amortization	2,122	2,376
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	24,933	23,003
Total operating (loss) income	(4,287)	637
Operating Segments [Member] \| Medical Device [Member]
Segment Reporting Information [Line Items]
Revenue	19,018	16,908
Total operating (loss) income	(7,235)	(3,792)
Depreciation and amortization	1,953	2,194
Operating Segments [Member] \| In Vitro Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	5,915	6,095
Total operating (loss) income	2,948	3,155
Depreciation and amortization	77	86
Corporate Non Segment [Member]
Segment Reporting Information [Line Items]
Total operating (loss) income	(2,942)	(2,804)
Depreciation and amortization	$ 92	$ 96

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 24,933	$ 23,003
Operating costs and expenses:
Cost, Product and Service [Extensible Enumeration]	Product Sales [Member]	Product Sales [Member]
Product costs	$ 5,267	$ 4,497
Research and development	12,743	11,663
Selling, general and administrative	13,236	9,192
Acquired intangible asset amortization	913	1,089
Contingent consideration expense	3	3
Total operating costs and expenses	32,162	26,444
Operating loss	(7,229)	(3,441)
Other expense:
Interest expense, net	(826)	(136)
Foreign exchange (loss) gain	(125)	33
Investment income, net	172	26
Other expense	(779)	(77)
Loss before income taxes	(8,008)	(3,518)
Income tax benefit	165	706
Net loss	$ (7,843)	$ (2,812)
Basic net loss per share	$ (0.56)	$ (0.20)
Diluted net loss per share	$ (0.56)	$ (0.20)
Weighted average number of shares outstanding:
Basic	13,983	13,878
Diluted	13,983	13,878
Product Sales [Member]
Revenue:
Total revenue	$ 14,234	$ 12,344
Royalties and License Fees [Member]
Revenue:
Total revenue	8,765	8,099
Research, Development and Other [Member]
Revenue:
Total revenue	$ 1,934	$ 2,560

Collaborative Arrangement

3 Months Ended

Dec. 31, 2022

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Collaborative Arrangement

3. Collaborative Arrangement

On February 26, 2018, the Company entered into an agreement with Abbott Vascular, Inc. (“Abbott”) whereby Abbott has exclusive worldwide commercialization rights for Surmodics' SurVeilTM drug-coated balloon (“DCB”) to treat the superficial femoral artery (the “Abbott Agreement”). A premarket approval (“PMA”) application for the SurVeil DCB was being evaluated by the U.S. Food and Drug Administration (“FDA” or the “Agency”) as of December 31, 2022. In January 2023, the FDA issued a letter to the Company indicating that the PMA application was not approvable based on the information submitted to the Agency to that time. The letter provided specific guidance on information, including additional testing and analysis, that would be required to put the application in approvable form.

Surmodics is responsible for conducting all necessary clinical trials and other activities required to achieve U.S. regulatory clearance for the SurVeil DCB, including completion of the ongoing TRANSCEND pivotal clinical trial. Abbott and Surmodics participate on a joint development committee charged with providing guidance on the Company’s clinical and regulatory activities with regard to the SurVeil DCB product. Upon receipt of U.S. regulatory approval for our SurVeil DCB, Abbott will have the right to purchase commercial units from the Company, and Surmodics will realize revenue from product sales to Abbott at an agreed-upon transfer price, as well as a share of net profits resulting from third-party product sales by Abbott.

As of December 31, 2022, the Company had received payments totaling $60.8 million under the Abbott Agreement, which consist of the following: (i) $25 million upfront fee in fiscal 2018, (ii) $10 million milestone payment in fiscal 2019, (iii) $10.8 million milestone payment in fiscal 2020, and (iv) $15 million milestone payment in fiscal 2021. As of December 31, 2022, the Abbott Agreement provides that the Company may receive an additional contingent milestone payment upon PMA of our SurVeil DCB of $27 million (if PMA is received prior to June 30, 2023) or $24 million (if PMA is received on or after June 30, 2023). As of December 31, 2022, consideration from this potential regulatory milestone was fully excluded from the contract price (i.e., deemed fully constrained) due to the high level of uncertainty of achievement as of December 31, 2022. If PMA is not received by December 31, 2023, Abbott may terminate the Abbott Agreement and would have no further obligation to make the potential regulatory milestone payment after termination. In the period of termination, deferred revenue on the condensed consolidated balance sheets related to payments received under the Abbott Agreement would be recognized as revenue.

Revenue recognized from the Abbott Agreement totaled $1.3 million and $1.2 million for the three months ended December 31, 2022 and 2021, respectively. The amount of revenue recognized from the Abbott Agreement that was included in the respective beginning of fiscal year balances of deferred revenue on the condensed consolidated balance sheets totaled $1.3 million and $1.2 million for the three months ended December 31, 2022 and 2021, respectively.

As of December 31, 2022 and September 30, 2022, deferred revenue on the condensed consolidated balance sheets included $7.9 million and $9.2 million, respectively, related to payments received under the Abbott Agreement. The $7.9 million deferred revenue as of December 31, 2022, which represents the Company’s performance obligations that are unsatisfied for executed contracts with an original duration of one year, is expected to be recognized as revenue over the next three years through fiscal 2025 as services, principally the TRANSCEND clinical trial, are completed.

Revenue (Tables)

3 Months Ended

Dec. 31, 2022

Revenue From Contract With Customer [Abstract]

Summary of Revenues Disaggregated by Product Classification and Reportable Segment

The following table presents the Company’s revenues disaggregated by product classification and by reportable segment.


	Three Months Ended December 31,
(In thousands)	2022		2021
Medical Device
Product sales	$	8,380	$	6,788
Royalties		7,409		6,886
License fees		1,356		1,213
Research, development and other		1,873		2,021
Medical Device Revenue		19,018		16,908
In Vitro Diagnostics
Product sales		5,854		5,556
Research, development and other		61		539
In Vitro Diagnostics Revenue		5,915		6,095
Total Revenue	$	24,933	$	23,003

Stock-based Compensation Plans - Stock-based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,965	$ 1,680
Product costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	67	30
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	374	453
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,524	$ 1,197

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Dec. 31, 2022	Feb. 03, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Trading Symbol	SRDX
Security Exchange Name	NASDAQ
Entity Registrant Name	Surmodics, Inc.
Entity Central Index Key	0000924717
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, $0.05 par value
Entity File Number	0-23837
Entity Incorporation, State or Country Code	MN
Entity Tax Identification Number	41-1356149
Entity Address, Address Line One	9924 West 74th Street
Entity Address, City or Town	Eden Prairie
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55344
City Area Code	952
Local Phone Number	500-7000
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		14,125,000

Net Loss Per Share Data

3 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Net Loss Per Share Data

. Net Loss Per Share Data

Basic net loss per common share is calculated by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options and non-vested stock relating to restricted stock awards and restricted stock units. For the three months ended December 31, 2022 and 2021, 0.1 million and 0.2 million in weighted-average shares, respectively, were excluded from the calculation of diluted net loss per share as their effect was anti-dilutive as a result of the net loss incurred for those periods. Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the three months ended December 31, 2022 and 2021.

The following table presents the denominator for the computation of diluted weighted average shares outstanding:


	Three Months Ended
	December 31,
(In thousands)	2022		2021
Basic weighted average shares outstanding		13,983		13,878
Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units		—		—
Diluted weighted average shares outstanding		13,983		13,878

Debt (Tables)

3 Months Ended

Dec. 31, 2022

Debt Disclosure [Abstract]

Schedule of Debt

Debt consisted of the following:


	December 31,			September 30,
(In thousands)	2022			2022
Short-term borrowings (1)	$	—		$	10,000

Revolving Credit Facility, Term SOFR + 3.00%, maturing October 1, 2027	$	5,000		$	—
Tranche 1 Term Loans, Term SOFR +5.75%, maturing October 1, 2027		25,000			—
Long-term debt, gross		30,000			—
Less: Unamortized debt issuance costs		(505	)		—
Long-term debt, net	$	29,495		$	—

(1)

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended				24 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2018	Sep. 30, 2024
Vetex Medical Limited [Member]
Commitments And Contingencies [Line Items]
Cash paid			$ 39,900,000
Deferred consideration, contractual value			$ 3,500,000
Installment payment beginning period			2024
Installment payment ending period			2027
Contingent consideration, contractual value			$ 3,500,000
Contingency period ending year			2027
Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Contingent payments upon achievement of regulatory milestones	$ 1,000,000.0
Installment payment beginning period	2023
Installment payment ending period	2024
CRO [Member]
Commitments And Contingencies [Line Items]
Contractual obligation remaining to be paid	$ 5,000,000
CRO [Member] \| Minimum [Member]
Commitments And Contingencies [Line Items]
Gross contractual obligation	37,000,000
CRO [Member] \| Maximum [Member]
Commitments And Contingencies [Line Items]
Gross contractual obligation	40,000,000
CRO [Member] \| Maximum [Member] \| CRO Pass-through Expenses [Member]
Commitments And Contingencies [Line Items]
Gross contractual obligation	$ 30,000,000
In Process Research and Development \| Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Contingency period ending year	2033
Payments to acquire in-process research and development		$ 500,000	$ 1,000,000.0	$ 1,000,000.0	$ 5,000,000.0
In Process Research and Development \| Embolitech LLC [Member] \| Forecast [Member]
Commitments And Contingencies [Line Items]
Contractual obligation payable in fiscal 2022 through fiscal 2024						$ 2,000,000.0

Collaborative Arrangement - Additional Information (Detail 1) - Abbott Agreement [Member] - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-01-01 $ in Millions	Dec. 31, 2022 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligation, amount	$ 7.9
Remaining performance obligation, satisfaction period	3 years

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Activities:
Net loss	$ (7,843)	$ (2,812)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,122	2,376
Stock-based compensation	1,965	1,680
Noncash lease expense	159	91
Amortization of debt issuance costs	78	11
Provision for credit losses	59	4
Deferred taxes	(107)	(640)
Other	78	66
Change in operating assets and liabilities:
Accounts receivable and contract assets	546	1,547
Inventories	(905)	(1,570)
Prepaids and other	(1,857)	(1,432)
Accounts payable	(1,254)	200
Accrued liabilities	(4,700)	(5,227)
Income taxes	2,218	(95)
Deferred revenue	(1,361)	(1,225)
Net cash used in operating activities	(10,802)	(7,026)
Investing Activities:
Purchases of property and equipment	(977)	(782)
Maturities of available-for-sale securities		4,000
Net cash (used in) provided by investing activities	(977)	3,218
Financing Activities:
Payments of short-term borrowings	(10,000)
Proceeds from issuance of long-term debt	29,664
Payments of debt issuance costs	(353)
Issuance of common stock	347	230
Payments for taxes related to net share settlement of equity awards	(858)	(853)
Net cash provided by (used in) financing activities	18,800	(623)
Effect of exchange rate changes on cash	411	(72)
Net change in cash and cash equivalents	7,432	(4,503)
Cash and Cash Equivalents:
Beginning of period	18,998	31,153
End of period	26,430	26,650
Supplemental Information:
Cash paid for income taxes	5	3
Cash paid for interest	660	82
Noncash investing and financing activities:
Acquisition of property and equipment, net of refundable credits in other current assets and liabilities	$ 150	137
Right-of-use assets obtained in exchange for new operating lease liabilities		$ 350

Segment Information

3 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Segment Information

12. Segment Information

Segment revenue, operating loss, and depreciation and amortization were as follows:


	Three Months Ended
	December 31,
(In thousands)	2022			2021
Revenue:
Medical Device	$	19,018		$	16,908
In Vitro Diagnostics		5,915			6,095
Total revenue	$	24,933		$	23,003

Operating (loss) income:
Medical Device	$	(7,235	)	$	(3,792	)
In Vitro Diagnostics		2,948			3,155
Total segment operating (loss) income		(4,287	)		(637	)
Corporate		(2,942	)		(2,804	)
Total operating (loss) income	$	(7,229	)	$	(3,441	)

Depreciation and amortization:
Medical Device	$	1,953		$	2,194
In Vitro Diagnostics		77			86
Corporate		92			96
Total depreciation and amortization	$	2,122		$	2,376

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Supplemental Balance Sheet Information - Schedule of Accrued Other Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 264	$ 279
Accrued clinical study expense	1,903	1,425
Accrued purchases	1,562	1,655
Acquisition of in-process research and development	1,933	981
Operating lease liability, current portion	1,027	963
Other	359	551
Total accrued other liabilities	$ 7,048	$ 5,854

Income Taxes

3 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

. Income Taxes

For interim income tax reporting, the Company estimates its annual effective tax rate and applies it to fiscal year-to-date pretax loss, excluding unusual or infrequently occurring discrete items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company reported income tax benefit of $0.2 million and $0.7 million for the three months ended December 31, 2022 and 2021, respectively.

Each reporting period, we evaluate the realizability of our net deferred tax assets and perform an assessment of both positive and negative evidence. Based on our evaluation of all available positive and negative evidence, and by placing greater weight on the objective negative evidence associated with our three-year cumulative U.S. pre-tax loss adjusted for permanent adjustments, we determined, as of December 31, 2022 and September 30, 2022, that it is more likely than not that our net U.S. deferred tax assets will not be realized. Accordingly, a full valuation allowance is recorded against our net U.S. deferred tax assets as of December 31, 2022 and September 30, 2022. Due to significant estimates used to establish the valuation allowance and the potential for changes in facts and circumstances, it is reasonably possible that we will be required to record additional adjustments to the valuation allowance in future reporting periods that could have a material effect on our results of operations.

In addition to the impact of the valuation allowance against our U.S. deferred tax assets, recurring items cause our effective tax rate to differ from the U.S. federal statutory rate of 21%, including U.S. federal and Irish R&D credits, Irish and U.S. state tax rates, and excess tax benefits associated with stock-based compensation.

The Company recognized discrete tax benefits related to stock-based compensation awards vested, expired, canceled and exercised of $0.1 million for each of the three months ended December 31, 2022 and 2021. The total amount of unrecognized tax benefits, excluding interest and penalties that, if recognized, would affect the effective tax rate was $3.0 million and $2.5 million as of December 31, 2022 and September 30, 2022, respectively. Interest and penalties related to unrecognized tax benefits are recorded in the income tax benefit.

The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions, as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. The Internal Revenue Service commenced an examination of the Company’s fiscal 2019 U.S. federal tax return in fiscal 2022; the examination has not been completed. U.S. federal income tax returns for years prior to fiscal 2019 are no longer subject to examination by federal tax authorities. For tax returns for U.S. state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2012. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2018. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical, Ltd.; NorMedix, Inc.; and Vetex for periods prior to the respective acquisition dates, pursuant to the terms of the related share purchase agreements. There were no undistributed earnings in foreign subsidiaries as of December 31, 2022 and September 30, 2022.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Supplemental Balance Sheet Information - Summary of Other Noncurrent Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022
Schedule Of Investments [Line Items]
Other assets	$ 5,006	$ 4,769
Operating Lease Right-of-Use Assets [Member]
Schedule Of Investments [Line Items]
Other assets	3,480	3,633
Other [Member]
Schedule Of Investments [Line Items]
Other assets	$ 1,526	$ 1,136

Revenue - Summary of Revenues Disaggregated by Product Classification and Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disaggregation Of Revenue [Line Items]
Total revenue	$ 24,933	$ 23,003
Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	14,234	12,344
Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	8,765	8,099
Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,934	2,560
Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	24,933	23,003
Operating Segments [Member] \| Medical Device [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	19,018	16,908
Operating Segments [Member] \| Medical Device [Member] \| Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	8,380	6,788
Operating Segments [Member] \| Medical Device [Member] \| Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	7,409	6,886
Operating Segments [Member] \| Medical Device [Member] \| License Fees [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,356	1,213
Operating Segments [Member] \| Medical Device [Member] \| Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,873	2,021
Operating Segments [Member] \| In Vitro Diagnostics [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	5,915	6,095
Operating Segments [Member] \| In Vitro Diagnostics [Member] \| Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	5,854	5,556
Operating Segments [Member] \| In Vitro Diagnostics [Member] \| Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 61	$ 539

- Definition

+ References

+ Details

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive (Loss)Income [Member]	Retained Earnings [Member]
Beginning balance at Sep. 30, 2021	$ 140,085	$ 695	$ 21,598	$ 1,727	$ 116,065
Beginning balance, shares at Sep. 30, 2021		13,899
Net loss	(2,812)				(2,812)
Other comprehensive income (loss), net of tax	(1,652)			(1,652)
Issuance of common stock		$ 4	(4)
Issuance of common stock ,shares		81
Common stock options exercised, net	230	$ 1	229
Common stock option exercise ,shares		14
Purchase of common stock to pay employee taxes	(860)	$ (1)	(859)
Purchase of common stock to pay employee taxes ,shares		(19)
Stock-based compensation	1,680		1,680
Ending balance at Dec. 31, 2021	136,671	$ 699	22,644	75	113,253
Ending balance ,shares at Dec. 31, 2021		13,975
Beginning balance at Sep. 30, 2022	108,392	$ 701	28,774	(9,874)	88,791
Beginning balance, shares at Sep. 30, 2022		14,029
Net loss	(7,843)				(7,843)
Other comprehensive income (loss), net of tax	5,257			5,257
Issuance of common stock		$ 5	(5)
Issuance of common stock ,shares		103
Common stock options exercised, net	347	$ 1	346
Common stock option exercise ,shares		17
Purchase of common stock to pay employee taxes	(857)	$ (1)	(856)
Purchase of common stock to pay employee taxes ,shares		(23)
Stock-based compensation	1,965		1,965
Ending balance at Dec. 31, 2022	$ 107,261	$ 706	$ 30,224	$ (4,617)	$ 80,948
Ending balance ,shares at Dec. 31, 2022		14,126

Subsequent Events Additional Information (Details) - Scenario Forecast [Member] $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Subsequent Event [Line Items]
Workforce reduction percentage	13.00%
Minimum [Member]
Subsequent Event [Line Items]
Restructuring and related cost, expected cost	$ 1.0
Maximum [Member]
Subsequent Event [Line Items]
Restructuring and related cost, expected cost	$ 1.2

Supplemental Balance Sheet Information - Schedule of Other Long-term Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Sep. 30, 2022
Other Liabilities Disclosure [Abstract]
Deferred consideration	$ 3,361	$ 4,260
Contingent consideration	832	829
Unrecognized tax benefits	1,741	1,841
Operating lease liabilities	3,584	3,843
Other long-term liabilities	$ 9,518	$ 10,773